Sponsored Links
BRIEF-ZIOPHARM jumps in premarket after palifosfamide reached target number of progression-free survival events
NEW YORK |
NEW YORK Feb 12 (Reuters) - ZIOPHARM Oncology Inc : * Jumps 14.5 percent to $4.57 in premarket after palifosfamide reached target number of progression-free survival events
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters